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In Plasmodium berghei infections, the mortality rate and parasitaemias were significantly reduced and the 
mean survival time was considerably enhanced by pretreating the animals with a tuftsin derivative, Thr-Lys- 
Pro-Arg-NH-(CH&-NHCOCrsHsr. This effect of the modified tuftsin was further increased upon its incor- 
poration in the liposome bilayer. These results indicate that tuftsin and its derivatives may prove useful 
in enhancing nonspecific host resistance against protozoan infections. 
Protozoan infection Immunomodulation 
1. INTRODUCTION 
The tetrapeptide tuftsin (Thr-Lys-Pro-Arg) 
resembles an integral component of IgG and is 
released physiologically as the free peptide frag- 
ment after enzymatic cleavage [l]. Several studies 
have shown that this peptide is a potent natural 
killer activator of phagocytic cells including 
macrophages [2-61. Since activated macrophages 
have been demonstrate&l to kill intraerythrocytic 
malarial parasites in vitro [7], we considered it of 
interest to examine the effect of tuftsin and its 
derivatives on Plasmodium berghei infection in 
mice. Our present data clearly show that pretreat- 
ment with the tuftsin derivative II (fig.1) 
significantly enhances the mean survival time and 
reduces the parasitaemias in infected animals. 
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Fig. 1. Hydrophobic derivatives of the tetrapeptide Thr- 
Lys-Pro-Arg (tuftsin). 
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2. MATERIALS AND METHODS 
2.1. Animals 
Randomly bred male Swiss mice weighing 20 f 
1 g were used in all experiments reported here. The 
animals had access to food (pellet diet, Hindustan 
Lever, Bombay) and water ad libitum. 
2.2. Parasite 
P. berghei parasite was obtained from the Na- 
tional Institute of Communicable Diseases, New 
Delhi, and maintained in Swiss mice through serial 
blood passage. 
2.3. Tuftsin and its derivatives 
Tuftsin and its derivatives (fig.1, I and II) were 
synthesized and characterized as in [8]. 
2.4. Liposomes 
Liposomes were prepared from equimolar 
amounts of egg phosphatidylcholine (PC) and 
cholesterol with or without II (8% by egg PC wt) 
in Tris-buffered saline (10 mM Tris containing 
150 mM NaCl, pH 7.4) by probe sonication [8]. 
The sonicated preparation was centrifuged at 
15 000 x g for 30 min ( 10°C) to sediment un- 
dispersed lipids and titanium particles. The 
amount of II incorporated in the liposome bilayer 
was estimated as in [8]. 
2.5. Animal experiments 
Tuftsin or one of its derivatives in Tris-buffered 
saline (0.5 ml) was administered intravenously to 
Table 1 
Effect of tuftsin and its derivatives on mean survival 
time of mice infected with P. berghei 
Animal Total Animals Mean 
group number of surviving survival 
animals onday +12 time(kSD) 
Control 20 0 8.7 + 1.6 
Tuftsin- 
treated 10 3 10.4 f 2.9 
I-treated 10 0 9.2 + 2.5 
II-treated 10 5 14.2 f 6.8 
Tuftsin or one of its derivatives was given on days - 3 
to 0. The dose of these peptides/animal per day was 
50 Pg 
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mice prior to or after the infection. The animals 
were challenged with 1 x lo6 parasitized 
erythrocytes/mouse intraperitoneally, and kept 
under observation to record parasitaemias and 
mortality. Parasitaemia was determined by coun- 
ting 104 red cells in a thin blood smear stained with 
Giemsa, and expressed as the number of parasitiz- 
ed cells/100 erythrocytes. The animals that were 
given only Tris-buffered saline (0.5 ml) or egg PC- 
cholesterol liposomes were used as controls. The 
day of challenge was referred to as day zero while 
other days were referred to as minus or plus 
(before and after challenge, respectively) to in- 
dicate the day of treatment with tuftsin and its 
derivatives. 
3. RESULTS AND DISCUSSION 
Mice that were pretreated with tuftsin or one of 
its derivatives were challenged with P. berghei, and 
their mortality and parasitaemias were recorded up 
to day +21. The animals in both the control and 
treated groups started dying from day + 7 and all 
the animals in control and I-treated groups suc- 
cumbed to infection by day + 12 (table 1). 
However, under identical conditions, about 30% 
animals from the tuftsin-treated group and 50% 
animals from the II-treated group survived on day 
+ 12. Moreover, the mean survival time of the 
animals that received pretreatment with II was 
significantly @ c 0.001) greater than that of the 
control group. Further, although the rate of in- 
crease of parasitaemia in II-treated animals was 
similar to that observed in control mice up to day 
+7, the parasitaemia levels in II-treated animals 
did not increase further at least up to day + 17. 
These results clearly demonstrate that mice 
pretreated with II are partially protected against 
lethal P. berghei infection. A pretreatment dose of 
50/cg/animal per day of II for more than 1 day 
seems to be necessary to obtain this partial protec- 
tion, since the mortality rate in animals pretreated 
with a single dose (2OOpg) on day - 3 or with 
lower doses (10 or 25 pg) on days 0 to - 3 was very 
similar to that observed in the saline-treated 
animals. 
Further experiments were done to ascertain 
whether enhanced uptake of II by phagocytic cells 
would increase its effect on P. berghei infection. 
As liposomes are known to localize primarily in 
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tissues rich in these cells [9], we speculated that up- 
take of II by the cells may further increase by in- 
corporating it in the liposome bilayer. To examine 
this possibility liposomes containing varying 
amounts of II in their bilayer were administered to 
mice before and after challenging them with P. 
berghei and mortality as well as parasitaemias 
recorded. Fig.2 shows that both the mortality rate 
and parasitaemias in the animals that received 
pretreatment with egg PC-cholesterol-II liposomes 
were significantly reduced, as compared with those 
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Fig.2. Parasitaemias in P. berghei-infected mice that 
received pretreatment on days -3 to 0 with egg PC- 
cholesterol-II liposomes. The doses of liposomised II
were 50 /g/animal per day (A) and 100 pg/animal per 
day (A). The animals that were given Tris-buffered 
saline (0) and egg PC-cholesterol liposomes (0) were 
used as controls. Values shown are means f SD. The 
figures shown on each point represent the number of 
mice surviving on that day. No mortality in any of these 
four groups was observed up to day + 6. For the sake of 
clarity only the mean values of parasitaemias are shown 
in the control groups. 
pretreated with saline or egg PC-cholesterol 
liposomes. However, similar treatment on days 0 
to + 3 did not confer much protection (fig.3). 
Besides, a better response was observed if the 
pretreatment dose of II was about 100 pg/animal 
per day instead of 50 gg/animal per day. This dose 
was optimal, as increasing the dose to 200,~g 
resulted in lower protection (fig.4). These results 
clearly show that II upon incorporation into the 
liposome bilayer still retains its antiparasitic activi- 
ty. The mean survival times of mice pretreated 
with 50 and 1OOpg doses of II in liposomes were 
about 16 and 19 days respectively (fig.4), which 
were greater than that observed with II in free 
form (table 1). 
The present study shows that in P. berghei infec- 
tion parasitaemias and mortality rates are 
h 
Fig.3. Parasitaemias in P. berghei-infected mice that 
were treated on days 0 to + 3 with egg PC-cholesterol-II 
liposomes. For other details see fig.2. 
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Fig.4. Survival time of mice that received treatment with 
egg PC-cholesterol-II liposomes, before or after the P. 
berghei infection. I, mice treated with saline; II, mice 
treated with egg PC-cholesterol liposomes; III, mice 
treated with 50 ,ug/animal per day dose of liposomised II 
on days 0 to + 3; IV, mice treated with 50 rg/animal per 
day dose of liposomised II on days - 3 to 0; V, mice 
treated with 100 @g/animal per day dose of liposomised 
II on days 0 to + 3; VI, mice treated with 100 ag/animal 
per day dose of liposomised II on days - 3 to 0; VII, 
mice treated with 2OOag/animal per day dose of 
liposomised II on days -3 to 0. Values shown are 
means f SD. Figures shown in parentheses represent he 
total number of animals taken in each group. 
significantly reduced in II-treated animals as com- 
pared with untreated infected controls. Also, the 
survival time of the infected mice is considerably (JJ 
< 0.001) enhanced by their pretreatment with the 
tuftsin derivative. This protective effect of II 
against P. berghei infection should arise probably 
from II-induced stimulation of macrophages and 
other related cells [2-61. 
Suppression of host immune response seems to 
be a general feature in almost all parasitic diseases 
[lo]. Agents that can bring the immune status back 
to normal should therefore find an important ap- 
plication in controlling the disease. In this context, 
several molecules of natural and synthetic origin, 
which possess trong immunomodulatory activity, 
have been examined for their antiparasitic action 
[ 111, but none of them appears to induce as mark- 
ed a resistance against protozoan infections as 
observed in the present study. We, therefore, con- 
clude that tuftsin and its derivatives could prove 
useful in enhancing nonspecific resistance against 
protozoan and other parasitic infections. 
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